Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 10-K Report Annual Report
  2. 8-K Event Results of operations
  3. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  4. 4 Grant or award SVP, Chief Technical Officer acquired 31,755 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. 8-K Event Material agreement
  7. 4 Planned sale Director sold 13,313 shares at $2.43 ($32,351)
  8. 144 Insider Sale of Securities
  9. SCHEDULE 13G Stake Statement of Beneficial Ownership
  10. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  11. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  12. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  13. 4 Open-market sale SVP, General Counsel sold 6,404 shares at $1.71 ($10,951)
  14. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 4,361 shares at $1.73 ($7,545)
  15. 4 Open-market sale Chief Technical Officer sold 14,746 shares at $1.71 ($25,216)
  16. 4 Open-market sale President and CEO sold 46,003 shares at $1.68 ($77,285)
  17. 4 Open-market sale EVP of R&D sold 18,832 shares at $1.70 ($32,014)
  18. 144 Insider Sale of Securities
  19. 144 Insider Sale of Securities
  20. 144 Insider Sale of Securities

Page 7 of 30 · 587 filings